^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
GENE:

JAK2 (Janus kinase 2)

i
Other names: JTK10, THCYT3, JAK2, Janus Kinase 2, Tyrosine-Protein Kinase JAK2, JAK-2
1d
Copy-Neutral Loss of Heterzygosity in Myelofibrosis: Parallel Evaluation with Optical Genome Mapping and Single-Nucleotide Polymorphism Arrays. (PubMed, J Mol Diagn)
These findings demonstrate that OGM, particularly when analyzed with VIA, is a sensitive and reliable method for CN-LOH detection in MF. However, in the absence of broader validation, confirmation with orthogonal methods remains necessary.
Clinical • Journal
|
JAK2 (Janus kinase 2)
1d
Targeting DDX5 using FL118 suppresses mTOR signaling and tumorigenicity in JAK2V617F-driven myeloproliferative neoplasms. (PubMed, Int Immunopharmacol)
In a subcutaneous tumor model, in which Ba/F3 cells expressing JAK2V617F and EpoR were transplanted into nude mice, oral administration of FL118 significantly reduced tumor growth and hepatosplenomegaly. Collectively, these findings establish DDX5 as a promising therapeutic target in MPNs and underscore the potential of FL118 as a treatment strategy for JAK2V617F-driven disease.
Journal • JAK2V617F
|
JAK2 (Janus kinase 2) • DDX5 (DEAD-Box Helicase 5)
|
FL118
2d
Maedi infection modulates oncogenic and inflammatory signaling in ovine pulmonary adenomatosis through TLR4/NF-κB and JAK2/STAT3 pathways: A Trojan horse mechanism. (PubMed, Vet Microbiol)
Overall, these findings suggest that chronic Maedi infection may modulate the pulmonary microenvironment by influencing inflammatory, apoptotic, and oncogenic signaling pathways in OPA. This immunomodulatory interaction may be relevant for understanding host-virus dynamics in naturally occurring virus-induced lung tumors.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • JAK2 (Janus kinase 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • TLR4 (Toll Like Receptor 4)
3d
The clinical study on individualized treatment for advanced myeloproliferative neoplasms using integrated multi-omics approaches (ChiCTR2500111453)
P=N/A, N=10, Not yet recruiting, The Second Medical Center of Chinese PLA General Hospital​; The Second Medical Center of Chinese PLA General Hospital?
New trial
|
TP53 (Tumor protein P53) • JAK2 (Janus kinase 2) • ASXL1 (ASXL Transcriptional Regulator 1) • CALR (Calreticulin)
|
TP53 mutation • ASXL1 mutation • EZH2 mutation
|
decitabine
6d
Targeted Therapy for a Rare PDGFRB-Rearranged Myeloproliferative Neoplasm: A Case Report. (PubMed, Int J Mol Sci)
This allowed for targeted therapy with a tyrosine kinase inhibitor (TKI), leading to molecular remission monitored by RT-qPCR. This case highlights how a multidisciplinary approach can identify atypical transcripts in MPN, guiding targeted therapy with TK inhibitors, thus resulting in effective treatment and molecular remission.
Journal
|
ABL1 (ABL proto-oncogene 1) • JAK2 (Janus kinase 2) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • CALR (Calreticulin) • CCDC88C (Coiled-Coil Domain Containing 88C)
|
LDH elevation
|
imatinib
7d
Budd-Chiari Syndrome Secondary to Essential Thrombocythaemia Complicated by Acquired Von Willebrand Disease and Mimicking Hepatic Malignancy: A Case Report. (PubMed, Cureus)
The patient was managed with cytoreductive therapy; initially, hydroxycarbamide and anagrelide, later transitioned to ruxolitinib, alongside lifelong anticoagulation. At six-month follow-up, he demonstrated improved LFTs, stable blood counts, and no recurrent thrombotic events, with ongoing surveillance for variceal bleeding. This case underscores the importance of considering BCS in patients with ET and hepatic abnormalities, screening for AvWS to balance thrombotic/bleeding risks, and utilizing a multidisciplinary team (MDT) approach for optimal management.
Journal
|
JAK2 (Janus kinase 2)
|
Jakafi (ruxolitinib) • hydroxyurea
7d
ALLO-BAT: Study of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk Myelofibrosis (clinicaltrials.gov)
P=N/A, N=90, Active, not recruiting, University Health Network, Toronto | Recruiting --> Active, not recruiting
Enrollment closed
|
TP53 (Tumor protein P53) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • JAK2 (Janus kinase 2) • ASXL1 (ASXL Transcriptional Regulator 1) • SRSF2 (Serine and arginine rich splicing factor 2) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1) • CALR (Calreticulin)
|
TP53 mutation • ASXL1 mutation • EZH2 mutation • SRSF2 mutation • CALR mutation
|
Jakafi (ruxolitinib) • hydroxyurea
7d
CONCERTO: Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations (clinicaltrials.gov)
P2, N=29, Active, not recruiting, University of Utah | Recruiting --> Active, not recruiting
Enrollment closed
|
KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • FLT3 (Fms-related tyrosine kinase 3) • ABL1 (ABL proto-oncogene 1) • NRAS (Neuroblastoma RAS viral oncogene homolog) • BCR (BCR Activator Of RhoGEF And GTPase) • NF1 (Neurofibromin 1) • JAK2 (Janus kinase 2) • PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11)
|
BRAF mutation
|
Cotellic (cobimetinib)
8d
Cardamonin induces apoptosis of colorectal cancer cells via targeted inhibition of the JAK/STAT3/epithelial-mesenchymal transition (EMT) signaling axis. (PubMed, Front Pharmacol)
It also inhibited the JAK/STAT3 signaling pathway, promoted apoptosis, downregulated Ki-67 expression, and attenuated EMT progression. CDN inhibits CRC progression and induces apoptosis by targeting the JAK/STAT3/EMT signaling axis, suggesting that CDN is a promising therapeutic agent for CRC.
Journal
|
EGFR (Epidermal growth factor receptor) • ER (Estrogen receptor) • JAK2 (Janus kinase 2) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • JAK1 (Janus Kinase 1) • STAT3 (Signal Transducer And Activator Of Transcription 3) • IL1B (Interleukin 1, beta)
9d
Polycythemia vera and stiff-person syndrome: a case report. (PubMed, BMC Neurol)
This case highlights the diagnostic and therapeutic challenges of these conditions as well as the need for further exploration of potential shared molecular mechanisms between PV and SPS.
Journal • Tumor mutational burden
|
TMB (Tumor Mutational Burden) • JAK2 (Janus kinase 2)
10d
Diagnostic reassessment in myeloproliferative neoplasms: the value of functional iron parameters and JAK2 allelic burden. (PubMed, Ann Hematol)
TSI and JAK2 VAF outperform ferritin as diagnostic markers to differentiate PV from ET. Integrating functional iron parameters with molecular data improves diagnostic accuracy, particularly in clinically ambiguous cases, and supports their inclusion in MPN diagnostic algorithms.
Retrospective data • Journal
|
JAK2 (Janus kinase 2) • CALR (Calreticulin)
11d
The improvement effect and mechanism of traditional Chinese medicine on chemotherapy-induced diarrhea: a systematic review. (PubMed, Front Pharmacol)
The medications commonly used to improve CID include loperamide and octreotide...We found that TCM has a definite therapeutic effect in the treatment of CID, which reflected in multiple levels and multiple pathways, including Keap1/Nrf2, TLR4/NLRP3, TLR4/NF-κB, JAK2/STAT3, Wnt, AKT, and MAPK. The aim of this review was to provide some references for applying TCM to treat CID in clinic, and provide new insights into the critical path ahead of the development of innovative drugs in alleviating CID.
Review • Journal
|
JAK2 (Janus kinase 2) • STAT3 (Signal Transducer And Activator Of Transcription 3) • TLR4 (Toll Like Receptor 4) • NLRP3 (NLR Family Pyrin Domain Containing 3)
|
loperamide